|Title:||Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism||Authors:||Pérez Alenza, Dolores
Lopez, Mari Luz
Melián Limiñana, Carlos
|UNESCO Clasification:||310907 Patología||Keywords:||Trilostane
|Issue Date:||2006||Publisher:||1547-3317||Journal:||Journal of the American Animal Hospital Association||Abstract:||Trilostane is considered an efficacious and safe medication for canine pituitary-dependent hyperadrenocorticism (PDH). Its recommended frequency of administration is once daily. In this prospective study, the efficacy, toxicity, and long-term outcome of trilostane administered twice daily per os were evaluated in 44 dogs with PDH. Mean initial dose was 3.1 mg/kg q 12 hours, and mean final dose was 3.2 mg/kg q 12 hours. The final total daily dose was lower than previously reported for once-daily administration. The mean survival time for affected dogs was 930 days.||URI:||http://hdl.handle.net/10553/45834||ISSN:||1547-3317||DOI:||10.5326/0420269||Source:||Journal of the American Animal Hospital Association [ISSN 1547-3317], v. 42, p. 269-276|
|Appears in Collections:||Artículos|
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.